- OS Therapies Inc. **terminated its Equity Purchase Agreement** (ELOC) with Square Gate Capital Master Fund, LLC — Series 3, effective **August 26, 2025**.  **[1795091_0001213900-25-080484_ea025457901ex99-1_ostherap.htm:0]** **[1795091_0001213900-25-080484_ea0254579-8k_ostherap.htm:1]** 
- The ELOC previously provided the company with the right to sell up to **$15.0 million** of its common stock.  **[1795091_0001213900-25-080484_ea0254579-8k_ostherap.htm:1]** 
- The termination was prompted by a recent warrant exercise inducement and exchange offering that provided OS Therapies with **$4.2 million** in gross proceeds.  **[1795091_0001213900-25-080484_ea025457901ex99-1_ostherap.htm:0]** 
- These proceeds are expected to fund the company's operations into **mid-year 2026**, extending through the priority review voucher sunset date of **September 30, 2026**.  **[1795091_0001213900-25-080484_ea025457901ex99-1_ostherap.htm:0]** 
- No outstanding borrowings, advance notices, shares to be issued, or termination fees were due by either party in connection with the termination.  **[1795091_0001213900-25-080484_ea0254579-8k_ostherap.htm:1]**

OS Therapies (OSTX)